

Press Information

For Immediate Release



LAURUS SYNTHESIS INC. NAMES KELLY HAGEN AS MANAGER, BUSINESS

DEVELOPMENT

Woburn MA, November 14, 2016 – Laurus Synthesis Inc. announced that Kelly Hagen has joined the company as Manager, Business Development, covering the Northeast, Southeast and Midwest United States. In making the announcement, Stuart Needleman, President of Laurus Synthesis Inc., said, “Kelly Hagen brings exceptional pharmaceutical and biotech business development and sales experience to Laurus Synthesis. Her past accomplishments at Asymchem and Sunovion make her an ideal addition to our team, and coupled with Adam Goodsell’s ongoing business development efforts in Massachusetts, the company now has strong representation both nationally and regionally.”

As a Senior Business Development executive at Asymchem, Ms Hagen was responsible for selling high value chemistry and development services to C-Suite Level Executives and Scientists at pharmaceutical and biotechnology companies. At Asymchem, she significantly surpassed annual sales goals from 2012 to August of 2016. Before joining Asymchem, Ms. Hagen was a Respiratory Sales Specialist at Sunovion and a Specialty and Pharmaceutical Sales Consultant at Purdue Pharma and Novartis. Prior to these posts, she was with Novartis, serving as CIBA Vision Territory Account Manager.

Ms. Hagen holds a Bachelor of Arts Degree from the University of Connecticut.

For more information or to arrange an interview, contact Maria Garvey at maria@delfino.com or 914.747.1400. Photos are available; please call or email to request them.

###

Press Information

For Immediate Release



About Laurus Synthesis Inc.

Laurus Synthesis Inc. offers specialized laboratory services from a new, state-of-the-art drug development facility in Woburn, Massachusetts. From this site, the company assists clients in advancing their concepts along the best path to their next milestone. Laurus Synthesis chemists and project managers provide process development, method development, impurity identification services and route selection for APIs, as well as intermediates and key starting materials. In addition, a smooth technical transition to the products and services of Laurus Labs for scale-up and commercialization will be available as required. Laurus Synthesis Inc. is a subsidiary of Laurus Labs, one of India's top ten chemistry providers. For more information, please visit www.laurussynthesis.com.

About Laurus Labs

Based in Visakhapatnam, India, Laurus Labs Private Limited (Laurus) develops and manufactures active pharmaceutical ingredients (API), with a focus on anti-retroviral (ARV) and oncology products. The company supplies its APIs to several Indian and global pharmaceutical companies. In addition to the API business, Laurus offers contract research (chemical, analytical and formulation development) and manufacturing services to generic and innovative pharmaceutical companies. Laurus has world-class infrastructure, consisting of a state-of-the-art R&D and scale-up laboratory in Hyderabad and large-scale manufacturing facilities at Visakhapatnam. These facilities have been accredited by several international regulatory agencies including the US-FDA, UK-MHRA, Australian TGA and Korean FDA. The company has revenues approaching \$270 million and currently employs 2,000+ people. For more information, please visit www.lauruslabs.com.